Top

Published in:

01-07-2018 | Original Article

Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer

Authors: Egbert F. Smit, Edward B. Garon, Martin Reck, Federico Cappuzzo, Paolo Bidoli, Roger B. Cohen, Ling Gao, Lisa M. O’Brien, Pablo Lee, Annamaria Zimmermann, David R. Ferry, Allen S. Melemed, Maurice Pérol

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2018

Abstract

Purpose

Ramucirumab plus docetaxel improved survival in REVEL, a randomized phase 3 trial for patients with Stage IV non-small cell lung cancer after standard platinum-based chemotherapy. This exploratory analysis evaluated the exposure–response relationship of ramucirumab from REVEL.

Methods

Patients received ramucirumab (10 mg/kg) or placebo plus docetaxel (75 mg/m²) every 3 weeks. Pharmacokinetic samples were collected. A population pharmacokinetic analysis predicted ramucirumab minimum concentration after first-dose administration (C_min,1) and average concentration at steady state (C_ave,ss). Predicted C_min,1 and C_ave,ss were used to evaluate the relationship between ramucirumab exposure and efficacy and safety, respectively. Exposure–efficacy was assessed by Kaplan–Meier and Cox regression analyses; exposure–safety was assessed by ordered categorical analyses.

Results

Analyses included 376 patients treated with ramucirumab plus docetaxel and 366 patients treated with placebo plus docetaxel (364 for safety population). After adjusting for corresponding prognostic factors, the association between overall survival (OS) and C_min,1 was statistically significant (p = 0.0110), although progression-free survival (PFS) showed a marginal association (p = 0.0515). At high ramucirumab exposures (C_min,1), greater improvements (smaller hazard ratios) were seen for OS and PFS when stratified by C_min,1 exposure quartiles. A statistically significant correlation was observed between ramucirumab C_ave,ss and grade ≥ 3 febrile neutropenia and hypertension.

Conclusions

An association was observed between ramucirumab exposure and efficacy. Higher ramucirumab exposure was associated with improved clinical outcomes and increased toxicity in this analysis. Two exposure–response prospective randomized trials are being conducted to address causation (NCT02443883 and NCT02514551), with encouraging preliminary results (Ajani et al. in Ann Oncol 28:abstr 698P, 2017).

Available only for authorised users

Spratlin JL, Mulder KE, Mackey JR (2010) Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol 6:1085–1094. https://doi.org/10.2217/fon.10.75 CrossRefPubMed

Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O’Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28:780–787. https://doi.org/10.1200/JCO.2009.23.7537 CrossRefPubMedPubMedCentral

Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Perol M (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665–673. https://doi.org/10.1016/S0140-6736(14)60845-X CrossRefPubMed

Larkins E, Scepura B, Blumenthal GM, Bloomquist E, Tang S, Biable M, Kluetz P, Keegan P, Pazdur R (2015) U.S. Food and Drug Administration approval summary: ramucirumab for the treatment of metastatic non-small cell lung cancer following disease progression on or after platinum-based chemotherapy. Oncologist 20:1320–1325. https://doi.org/10.1634/theoncologist.2015-0221 CrossRefPubMedPubMedCentral

U.S. Department of Health and Human Services (2003) Guidance for industry, exposure–response relationships-study design, data analysis, and regulatory applications. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072109.pdf. Accessed 30 Aug 2015

Thurber GM, Schmidt MM, Wittrup KD (2008) Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60:1421–1434. https://doi.org/10.1016/j.addr.2008.04.012 CrossRefPubMedPubMedCentral

Cosson VF, Ng VW, Lehle M, Lum BL (2014) Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemother Pharmacol 73:737–747. https://doi.org/10.1007/s00280-014-2400-5 CrossRefPubMed

Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS (2013) Exposure–response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 19:3977–3986. https://doi.org/10.1158/1078-0432.CCR-12-3243 CrossRefPubMed

Wang J, Song P, Schrieber S, Liu Q, Xu Q, Blumenthal G, Amiri KL, Cortazar P, Ibrahim A, Justice R, Wang Y, Tang S, Booth B, Mehrotra N, Rahman A (2014) Exposure–response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. Clin Pharmacol Ther 95:558–564. https://doi.org/10.1038/clpt.2014.24 CrossRefPubMed

10.

Zhu M, Tang R, Doshi S, Oliner KS, Dubey S, Jiang Y, Donehower RC, Iveson T, Loh EY, Zhang Y (2015) Exposure–response analysis of rilotumumab in gastric cancer: the role of tumour MET expression. Br J Cancer 112:429–437. https://doi.org/10.1038/bjc.2014.649 CrossRefPubMedPubMedCentral

11.

Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G et al (2017) Exposure–response analyses of ramucirumab from two randomized, phase III trials of second-line treatment for advanced gastric or gastroesophageal junction cancer. Mol Cancer Ther 16:2215–2222. https://doi.org/10.1158/1535-7163.MCT-16-0895 CrossRefPubMed

12.

Cohn AL, Yoshino T, Heinemann V, Obermannova R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia-Alfonso P, Portnoy DC, Van Cutsem E, Yamazaki K, Clingan PR, Polikoff J, Lonardi S, O’Brien LM, Gao L, Yang L, Ferry D, Nasroulah F, Tabernero J (2017) Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. Cancer Chemother Pharmacol 80:599–608. https://doi.org/10.1007/s00280-017-3380-z CrossRefPubMedPubMedCentral

13.

Ajani JA, Udrea A, Sarosiek T, Shenker M, Morgan C, Pikiel J, Wojcik E, Swinson D, Joseph M, Luft A, Salek T, Tournigand C, Ferry D, Zhang Y, Long A, Kuo W-L, Gao L, Kauh J, Mansoor W (2017) A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB. Ann Oncol 28(suppl 5):abstr 698P

14.

O’Brien L, Westwood P, Gao L, Heathman M (2017) Population pharmacokinetic meta-analysis of ramucirumab in cancer patients. Br J Clin Pharmacol 83:2741–2751. https://doi.org/10.1111/bcp.13403 CrossRefPubMedPubMedCentral

15.

Yang J, Zhao H, Garnett C, Rahman A, Gobburu JV, Pierce W, Schechter G, Summers J, Keegan P, Booth B, Wang Y (2013) The combination of exposure–response and case–control analyses in regulatory decision making. J Clin Pharmacol 53:160–166. https://doi.org/10.1177/0091270012445206 CrossRefPubMed

16.

Rubin D (1980) Bias reduction using Mahalanobis metric matching. Biometrics 36:293–298CrossRef

17.

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31–39. https://doi.org/10.1016/S0140-6736(13)61719-5 CrossRefPubMed

18.

Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235. https://doi.org/10.1016/S1470-2045(14)70420-6 CrossRefPubMed

19.

Herbst RS, Sun Y, Eberhardt WE, Germonpre P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11:619–626. https://doi.org/10.1016/S1470-2045(10)70132-7 CrossRefPubMedPubMedCentral

20.

Jin R, Li H, Zhang LH, Zhao H, Fashoyin-Aje L, Lemery S, Keegan P, Booth B, Atiqur Rahman N, Wang Y, Sinha V, Zhao L (2015) Exposure–response (E–R) and case–control analyses of ramucirumab leading to recommendation for dosing optimization in patients with gastric cancer. J Clin Oncol 33(suppl):abstr 2578. https://doi.org/10.1200/jco.2015.33.15_suppl.2578 CrossRef

21.

Casak SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, Jin R, Li H, Zhao L, Zhao H, Zhang H, Chen H, He K, Dougherty M, Novak R, Kennett S, Khasar S, Helms W, Keegan P, Pazdur R (2015) FDA approval summary: ramucirumab for gastric cancer. Clin Cancer Res 21:3372–3376. https://doi.org/10.1158/1078-0432.CCR-15-0600 CrossRefPubMed

Title: Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer
Authors: Egbert F. Smit
Edward B. Garon
Martin Reck
Federico Cappuzzo
Paolo Bidoli
Roger B. Cohen
Ling Gao
Lisa M. O’Brien
Pablo Lee
Annamaria Zimmermann
David R. Ferry
Allen S. Melemed
Maurice Pérol
Publication date: 01-07-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3560-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study

Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer

Reduced dose pegfilgrastim is associated with less bone pain without increased neutropenia: a retrospective study

Sunitinib does not acutely alter left ventricular systolic function, but induces diastolic dysfunction

Possible association of CAG repeat polymorphism in KCNN3 encoding the potassium channel SK3 with oxaliplatin-induced neurotoxicity

Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer